Investor Presentaiton
Investor presentation
Full year 2018
Slide 36
Region Japan & Korea at a glance
Diabetes trend in population
Diabetes market by value and
Novo Nordisk market share
Novo Nordisk reported sales
Million
16
Population with diabetes
Diabetes growth rate
NN Insulin MS
NN OAD MS
bDKK
40
NN GLP-1 MS
Full year 2018
Sales
(mDKK)
Growth²
80%
Long-acting insulin³
857
1%
-9%
20%
Premix insulin4
650
(4%)
12
30
31.1%¹
+60%
12
11
GLP-1
Insulin
Fast-acting insulin5
779
(15%)
Human insulin
187
(17%)
12
(2.1%)¹
8 -
20
40%
Total insulin
2,473
(7%)
GLP-16
614
7%
4.8%¹
OAD
Other diabetes care?
368
1%
4
10
+ 20%
Diabetes care
3,455
(4%)
Obesity (SaxendaⓇ)
175
0
2000
2017
2045
Nov
2013
0%
Biopharm³
2,167
Nov
2018
(6%)
Total
5,797
(2%)
Japan & Korea population 2018: ~0.2 billion people and diabetes
prevalence ~8.0%
Source: International Diabetes Federation: Diabetes Atlas 1th Edition
2000 and Diabetes Atlas 8th Edition 2017
1 CAGR calculated for last 5-year period
Competitor value market share comparison for insulin as of Nov 2018:
Novo Nordisk 57%, Eli Lilly 22% and Sanofi 21%
Competitor value market share comparison for GLP-1 as of Nov 2018:
Novo Nordisk 33%, Eli Lilly 61%, Sanofi 3% and AstraZeneca 3%
OAD: Oral anti-diabetic; MS: Market share
Source: IQVIA MAT Nov, 2018 value figures
2 Percentage change in local currency from full year 2017 to full year
2018
3 Comprises TresibaⓇ and Levemir®: 4 Comprises NovoMix® and
RyzodegⓇ; 5 Comprises NovoRapidⓇ; 6 Comprises VictozaⓇ; 7 Comprises
NovoNormⓇ and needles; 8 Comprises primarily NovoSeven®,
NovoEight® NovoThirteenⓇ and NorditropinⓇView entire presentation